Holen Sie sich die Stockscreener-App
39.93
5.22%
1.98
Handel nachbörslich:
40.05
0.12
+0.30%
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex Therapeutics stock hits 52-week high at 39.16 USD - Investing.com
Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed? - simplywall.st
Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus - Sahm
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $54 - Moomoo
CLDX Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Pipeline ProgressEarnings Season Review - dars.gov.et
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Yahoo Finance
Form 4 Celldex Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity - Stock Titan
Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Celldex (NASDAQ: CLDX) CCO granted 90,000 stock options at $34.09 - Stock Titan
Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options - Stock Titan
Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant - Stock Titan
Celldex (CLDX) SVP granted 95,000 options at $34.09 strike - Stock Titan
Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant - Stock Titan
Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09 - Stock Titan
Celldex (NASDAQ: CLDX) grants 100,000 options to senior VP & CPDO - Stock Titan
Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP - Stock Titan
Celldex (CLDX) EVP & CSO awarded 115,000-share stock option grant - Stock Titan
Celldex (CLDX) CEO Anthony Marucci receives grant of 375,000 stock options - Stock Titan
Celldex (CLDX) director awarded 26,000-share stock option grant as compensation - Stock Titan
Celldex (CLDX) director receives grant of 26,000 stock options - Stock Titan
Celldex (CLDX) director James Marino awarded options on 26,000 shares - Stock Titan
Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options - Stock Titan
Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan - Stock Titan
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark - marketscreener.com
Celldex Therapeutics stock hits 52-week high at 35.8 USD - Investing.com
Celldex Therapeutics stock hits 52-week high at 35.8 USD By Investing.com - Investing.com South Africa
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2000 Growth Benchmark - marketscreener.com
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000E Growth Benchmark - marketscreener.com
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Enterprise value to EBITDA forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Enterprise value to EBITDA forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Price to earnings forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Enterprise value to revenue forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Price to book forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Celldex Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Celldex (CLDX) shareholders back larger equity plan and all directors - Stock Titan
Celldex Therapeutics (CLDX) Is Up 5.1% After Barzolvolimab, CDX-622 Mast-Cell Data UpdateWhat's Changed - Sahm
Celldex Therapeutics, Inc. Actuals & Estimates (NASDAQ:CLDX) - TradingView
CLDX Forecast — Price Target — Prediction for 2027 - TradingView
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight - PR Newswire
Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data - Sahm
Chronic Spontaneous Urticaria Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart
Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celldex Therapeutics Inc (CLDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celldex Therapeutics Inc (CLDX) Institutional Confidence - TradingKey
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics Inc (CLDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celldex Therapeutics StockUBS reiterates Buy after data update - AD HOC NEWS
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67 - Moomoo
Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study - TradingView
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting - Yahoo! Finance Canada
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):